Literature DB >> 18275682

Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake.

Carel W le Roux1, Cynthia M Borg, Kevin G Murphy, Royce P Vincent, Mohammad A Ghatei, Stephen R Bloom.   

Abstract

BACKGROUND: Peptide YY (PYY(3-36)) infused to levels within the physiological range reduces appetite and food intake in humans without nausea. However, PYY(3-36) has previously been shown to cause nausea at higher doses.
METHODS: We studied the relationship of PYY(3-36), nausea and food intake in six volunteers, using three different PYY(3-36) preparations infused to achieve supraphysiological PYY plasma levels.
RESULTS: Supraphysiological levels of PYY caused nausea in five subjects (P < 0.05). Although PYY(3-36) increased satiety (P < 0.05) and reduced food intake (P < 0.05), no greater enhancement of satiety or inhibition of food intake was observed compared with previous reports.
CONCLUSIONS: This study cautions against the use of supraphysiological doses of PYY(3-36) as it may increase nausea with no benefit in food reduction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18275682     DOI: 10.1258/acb.2007.007068

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  20 in total

Review 1.  Gut hormones: the future of obesity treatment?

Authors:  Anne K McGavigan; Kevin G Murphy
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

Review 2.  Bowels control brain: gut hormones and obesity.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Nat Rev Endocrinol       Date:  2010-06-29       Impact factor: 43.330

3.  Enteroendocrine cells: neglected players in gastrointestinal disorders?

Authors:  Gordon W Moran; Fiona C Leslie; Scott E Levison; J Worthington; John T McLaughlin
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

Review 4.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

5.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

6.  A Long-Acting PYY3-36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates.

Authors:  Shamina M Rangwala; Katharine D'Aquino; Yue-Mei Zhang; Lindsay Bader; Wilson Edwards; Songmao Zheng; Annette Eckardt; Ann Lacombe; Rebecca Pick; Veronica Moreno; Lijuan Kang; Wenying Jian; Eric Arnoult; Martin Case; Celia Jenkinson; Ellen Chi; Ronald V Swanson; Paul Kievit; Kevin Grove; Mark Macielag; Mark D Erion; Ranabir SinhaRoy; James N Leonard
Journal:  Cell Metab       Date:  2019-02-14       Impact factor: 27.287

Review 7.  CNS-targeting pharmacological interventions for the metabolic syndrome.

Authors:  Kerstin Stemmer; Timo D Müller; Richard D DiMarchi; Paul T Pfluger; Matthias H Tschöp
Journal:  J Clin Invest       Date:  2019-08-05       Impact factor: 14.808

Review 8.  Pharmacological management of appetite expression in obesity.

Authors:  Jason C G Halford; Emma J Boyland; John E Blundell; Tim C Kirkham; Joanne A Harrold
Journal:  Nat Rev Endocrinol       Date:  2010-03-16       Impact factor: 43.330

9.  Nutritive, Post-ingestive Signals Are the Primary Regulators of AgRP Neuron Activity.

Authors:  Zhenwei Su; Amber L Alhadeff; J Nicholas Betley
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

10.  PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.

Authors:  Benjamin C T Field; Alison M Wren; Veronique Peters; Kevin C R Baynes; Niamh M Martin; Michael Patterson; Sara Alsaraf; Vian Amber; Katie Wynne; Mohammad A Ghatei; Stephen R Bloom
Journal:  Diabetes       Date:  2010-03-31       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.